These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

87 related articles for article (PubMed ID: 8765669)

  • 61. Indolyl compounds as antiinflammatory agents.
    Verma M; Gujrati VR; Sharma M; Saxena AK; Bhalla TN; Sinha JN; Bhargava KP; Shanker K
    Arch Pharm (Weinheim); 1982 Apr; 315(4):358-63. PubMed ID: 7092514
    [No Abstract]   [Full Text] [Related]  

  • 62. Infrared studies on pig brain thromboplastin.
    Rezvan H; Howell RM
    Biochem Soc Trans; 1978; 6(1):235-7. PubMed ID: 640172
    [No Abstract]   [Full Text] [Related]  

  • 63. Development of CCK-B antagonists.
    Horwell DC
    Neuropeptides; 1991 Jul; 19 Suppl():57-64. PubMed ID: 1881533
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Conformationally restricted analogues of the potent CCK-B antagonist CI-988.
    Higginbottom M; Hill DR; Horwell DC; Mostafai E; Suman-Chauhan N; Roberts E
    Bioorg Med Chem; 1993 Sep; 1(3):209-17. PubMed ID: 8081854
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Cholecystokinin B antagonists. Synthesis and quantitative structure-activity relationships of a series of C-terminal analogues of CI-988.
    Augelli-Szafran CE; Horwell DC; Kneen C; Ortwine DF; Pritchard MC; Purchase TS; Roth BD; Trivedi BK; Hill D; Suman-Chauhan N; Webdale L
    Bioorg Med Chem; 1996 Oct; 4(10):1733-45. PubMed ID: 8931944
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Biochemical and pharmacological profiles of loxiglumide, a novel cholecystokinin-A receptor antagonist.
    Fukamizu Y; Nakajima T; Kimura K; Kanda H; Fujii M; Saito T; Kasai H
    Arzneimittelforschung; 1998 Jan; 48(1):58-64. PubMed ID: 9522034
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Synthesis and receptor binding affinity of cholecystokinin receptor ligands: 2-and 1-indolyl derivatives of PD134308.
    Araldi G; Donati D; Oliosi B; Ursini A; van Amsterdam F; Natalini B; Pellicciari R; Tarzia G
    Farmaco; 1996 Jul; 51(7):471-6. PubMed ID: 8765669
    [TBL] [Abstract][Full Text] [Related]  

  • 68. 'Targeted' molecular diversity: design and development of non-peptide antagonists for cholecystokinin and tachykinin receptors.
    Horwell D; Pritchard M; Raphy J; Ratcliffe G
    Immunopharmacology; 1996 Jun; 33(1-3):68-72. PubMed ID: 8856117
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Recent advances in the chemistry of cholecystokinin receptor ligands (agonists and antagonists).
    de Tullio P; Delarge J; Pirotte B
    Curr Med Chem; 1999 Jun; 6(6):433-55. PubMed ID: 10213792
    [TBL] [Abstract][Full Text] [Related]  

  • 70. [Cholecystokinin receptor antagonists].
    Ohtsuka T; Yokose K
    Tanpakushitsu Kakusan Koso; 1993 Aug; 38(11):1853-62. PubMed ID: 8210429
    [No Abstract]   [Full Text] [Related]  

  • 71. Neurochemical actions of CCK underlying the therapeutic potential of CCK-B antagonists.
    Hughes J; Hunter JC; Woodruff GN
    Neuropeptides; 1991 Jul; 19 Suppl():85-9. PubMed ID: 1679213
    [No Abstract]   [Full Text] [Related]  

  • 72. CI-1015. An orally active CCK-B receptor antagonist with an improved pharmacokinetic profile.
    Trivedi BK; Hinton JP
    Pharm Biotechnol; 1998; 11():481-505. PubMed ID: 9760693
    [No Abstract]   [Full Text] [Related]  

  • 73.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 74.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 75.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 76.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 77.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 78.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 79.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 80.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.